Toffoli G - Search Results

1

Proof-of-Concept Multistage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin.

Palazzolo S, Hadla M, Spena CR, Bayda S, Kumar V, Lo Re F, Adeel M, Caligiuri I, Romano F, Corona G, Canzonieri V, Toffoli G, Rizzolio F. Palazzolo S, et al. Among authors: toffoli g. ACS Med Chem Lett. 2019 Jan 31;10(4):517-521. doi: 10.1021/acsmedchemlett.8b00557. eCollection 2019 Apr 11. ACS Med Chem Lett. 2019. PMID: 30996789 Free PMC article.

2

Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.

Toffoli G, Corona G, Gigante M, Boiocchi M. Toffoli G, et al. Eur J Cancer. 1996 Aug;32A(9):1591-7. doi: 10.1016/0959-8049(96)00113-x. Eur J Cancer. 1996. PMID: 8911123

3

Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells.

Corona G, Giannini F, Fabris M, Toffoli G, Boiocchi M. Corona G, et al. Among authors: toffoli g. Int J Cancer. 1998 Jan 5;75(1):125-33. doi: 10.1002/(sici)1097-0215(19980105)75:1<125::aid-ijc19>3.0.co;2-f. Int J Cancer. 1998. PMID: 9426700 Free article.

4

Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients.

Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M. Toffoli G, et al. Int J Cancer. 2003 Jan 20;103(3):294-9. doi: 10.1002/ijc.10847. Int J Cancer. 2003. PMID: 12471611 Free article.

5

Pharmacogenetics of irinotecan.

Toffoli G, Cecchin E, Corona G, Boiocchi M. Toffoli G, et al. Curr Med Chem Anticancer Agents. 2003 May;3(3):225-37. doi: 10.2174/1568011033482477. Curr Med Chem Anticancer Agents. 2003. PMID: 12769780 Review.

6

Pharmacokinetic optimisation of treatment with oral etoposide.

Toffoli G, Corona G, Basso B, Boiocchi M. Toffoli G, et al. Clin Pharmacokinet. 2004;43(7):441-66. doi: 10.2165/00003088-200443070-00002. Clin Pharmacokinet. 2004. PMID: 15139794 Review.

7

Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin.

Toffoli G, Sorio R, Basso B, Aita P, Corona G, Rupolo M, Boiocchi M. Toffoli G, et al. J Chemother. 2004 Apr;16(2):193-200. doi: 10.1179/joc.2004.16.2.193. J Chemother. 2004. PMID: 15216956

8

UGT1A1*28 polymorphism in ovarian cancer patients.

Cecchin E, Russo A, Corona G, Campagnutta E, Martella L, Boiocchi M, Toffoli G. Cecchin E, et al. Among authors: toffoli g. Oncol Rep. 2004 Aug;12(2):457-62. Oncol Rep. 2004. PMID: 15254716

9

Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.

Toffoli G, Corona G, Cattarossi G, Boiocchi M, Di Gennaro G, Tirelli U, Vaccher E. Toffoli G, et al. Ann Oncol. 2004 Dec;15(12):1805-9. doi: 10.1093/annonc/mdh464. Ann Oncol. 2004. PMID: 15550586 Free article. Clinical Trial.

10

High throughput screening of genetic polymorphisms by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Corona G, Toffoli G. Corona G, et al. Among authors: toffoli g. Comb Chem High Throughput Screen. 2004 Dec;7(8):707-25. doi: 10.2174/1386207043328283. Comb Chem High Throughput Screen. 2004. PMID: 15578933 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

345 results

Search Page